Results 11 to 20 of about 178,708,228 (184)

RANK-Ligand inhibitor associated osteonecrosis of the jaw

GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2013
Osteonecrosis of the jaw may be caused by many different triggers. One of them is described to be the drug or medication related osteonecrosis of the jaw. Since many years bisphosphonates induced the dreaded diagnosis.
Rashad, Ashkan, Smeets, Ralf, Heiland, Max   +2 more
doaj   +2 more sources

Osteonecrosis of the Jaw

Dentistry Journal, 2023
Osteonecrosis of the jaw is a condition in which bone cells die due to various causes. It is classified as drug-induced jaw osteonecrosis, osteoradionecrosis, traumatic, non-traumatic, and spontaneous osteonecrosis. Antiresorptive or antiangiogenic drugs
Božana Lončar Brzak, Lorena Horvat Aleksijević, Ema Vindiš, Iva Kordić, Marko Granić, Danica Vidović Juras, Ana Andabak Rogulj   +6 more
doaj   +2 more sources

Intraosseous Squamous Cell Carcinoma Associated with Denosumab-Induced Osteonecrosis of the Jaw [PDF]

Applied Sciences, 2021
Medication-related osteonecrosis of the jaw (MRONJ) has been associated with the use of different drugs administered in the treatment of malignant neoplasms or metastases and in antiresorptive therapies. Since 2010, denosumab, a monoclonal antibody whose
Sandra Bacián Martínez, Carlos Navarro Cuéllar, Carlos Navarro Vila, Edurne Palacios Weiss, Roser Pujol Romanyá, Álvaro del Amo Fernández de Velasco, Margarita Escrig de Teijeiro, José Luis del Castillo Pardo de Vera, Irene Rodríguez Pérez, Arturo Sánchez-Pérez, José J. Zamorano-León, Antonio López-Farré, María Isabel García-Hidalgo Alonso, Ignacio Navarro Cuéllar   +13 more
doaj   +2 more sources

CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma

Haematologica, 2011
Osteonecrosis of the jaw is an uncommon but potentially serious complication of bisphosphonate therapy in multiple myeloma. Previous studies showed that the presence of one or two minor alleles of the cytochrome P450, subfamily 2C polypeptide 8 gene ...
Esperanza Such, José Cervera, Evangelos Terpos, José V Bagán, Amparo Avaria, Inés Gómez, María Margaix, Mariam Ibañez, Irene Luna, Lourdes Cordón, Mónica Roig, Miguel A. Sanz, Meletios A. Dimopoulos, Javier de la Rubia   +13 more
doaj   +3 more sources

The Validity of Claims-Based Algorithms to Identify Serious Hypersensitivity Reactions and Osteonecrosis of the Jaw. [PDF]

PLoS ONE, 2015
Validation of claims-based algorithms to identify serious hypersensitivity reactions and osteonecrosis of the jaw has not been performed in large osteoporosis populations.
Nicole C Wright, Jeffrey R Curtis, Tarun Arora, Wilson K Smith, Meredith L Kilgore, Kenneth G Saag, Monika M Safford, Elizabeth S Delzell   +7 more
doaj   +2 more sources

Imaging modalities for drug-related osteonecrosis of the jaw (2), Overview of the position paper on medication-related osteonecrosis of the jaw and the current status of the MRONJ in Japan

Japanese Dental Science Review, 2019
Summary: Since Marx reported on osteonecrosis of the jaw caused by the injectable bisphosphonates (BPs) pamidronate and zoledronate, there have been numerous reports not only in Western countries, but in Japan as well, of bisphosphonate-related ...
Takahiko Shibahara
exaly   +3 more sources

Bisphosphonate-Related Osteonecrosis of the Jaw Mimicking Bone Metastasis [PDF]

Case Reports in Oncological Medicine, 2014
Osteonecrosis of the jaw is usually a potential complication of bisphosphonate therapy. In a cancer patient, this disease entity can be misdiagnosed as a metastatic lesion. Our aim is to make clinicians aware of bisphosphonate associated osteonecrosis of
Geetika Bhatt, Aashish Bhatt, Anthony E. Dragun, Xiao-Feng Li, A. Cahid Civelek   +4 more
doaj   +2 more sources

The Use of Imaging Methods in the Diagnosis of Bisphosphonate-related Osteonecrosis of the Jaw

Česká Stomatologie a Praktické Zubní Lékařství, 2012
Objectives: Osteonecrosis of the jaws is a rare side effect of bisphosphonate therapy, occurring especially in oncological patients but also in patients with metabolic bone diseases.
L. Hauer, J. Baxa, D. Hrušák, L. Hostička, P. Andrle   +4 more
doaj   +2 more sources

What Do Prescribers of Bone Modifying Agents Know about Medication-Related Osteonecrosis of the Jaw? Is Current Prevention Enough?

Applied Sciences, 2022
Osteonecrosis of the jaw represents interference by external and internal factors in the natural bone remodeling system. Numerous bone remodeling agents (BMAs), such as bisphosphonates, denosumab, and tyrosine kinase inhibitors, can lead to medication ...
Mihai Vlad Golu, Ionela Pașcanu, Cornelia Togănel, Cecilia Petrovan, Adina Cosarcă, Despina Luciana Bereczki Temistocle, Alina Ormenișan   +6 more
doaj   +1 more source

Iatrogenic risk of osteonecrosis of the jaw? Bone substitutes for dental implants: a warning from Japan [PDF]

, 2020
2020-02Commercial bone substitutes that are widely used for bone augmentation for dental implants are predisposing factors in the development of osteonecrosis of the jaw (ONJ), overlooking this situation may lead to serious problems.
Hibi, Hideharu
core   +1 more source